Castellano, Jose Maria

Jose Maria Castellano, PhD

ADJUNCT ASSOCIATE PROFESSOR | Icahn School of Medicine at Mount Sinai Hospital
COORDINATOR, CLINICAL RESEARCH | Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid (Spain)
DIRECTOR, CARDIOVASCULAR HEALTH PROGRAM | Hospital Universitario Montepríncipe, Madrid (Spain)
ASSOCIATE PROFESSOR | Universidad CEU San Pablo, Madrid (Spain)

Specialty: Cardiovascular Medicine


After completing a BSc at Brown University, Providence, Rhode Island, Dr. Castellano gained his medical degree in 2005 at the University Clinic of Navarra in Spain. He subsequently completed a fellowship in Cardiology at the University of Navarra in 2010, where he obtained his PhD degree studying the role of Cardiotrophin-1 on cardiac structure and function in the context of the metabolic syndrome.

Dr. Castellano completed a PostDoc degree on advanced clinical research under the direction of Dr. Fuster at Mount Sinai Cardiovascular Institute in New York.

Currently, Dr. Castellano holds a position as adjunct Professor of Medicine at the Icahn School of Medicine at Mount Sinai Hospital.

He is currently the coordinator of Clinical Trials at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid,  Director of the Cardiovascular Health Program at Hospital Universitario Monteprincipe and Associate Professor of Medicine at CEU San Pablo. He is involved in numerous studies worldwide that study the various interventions in promotion of cardiovascular health and preventive cardiovascular medicine such as the SECURE trial (funded by H2020) and TANSNIP Study.

Read more

Clinical interests

General cardiology, cardiovascular imaging, heart failure, valvular heart disease, cardiomyopathies, promotion of health, coronary artery disease, metabolic syndrome, diabetes mellitus and diabetic cardiomyopathy, atrial fibrillation, diseases of the aorta, global health and social consequences of disease.



Bachelor of Sciences Biology

Brown University, Providence, Rhode Island | August 1993- May 1998

Medical Degree

Medical School, Universidad de Navarra, Spain| September 1998- June 2004

Cardiology Fellowship

Departamento de Cardiología y Cirugía Cardiovascular.

Clínica Universidad de Navarra, Pamplona, Spain | May 2005- May 2010

PhD in Cardiovascular Medicine

Medical School, Universidad de Navarra, Spain | May 2005- September 2010.

Senior Postdoctoral Investigator

Icahn School of Medicine at Mount Sinai

Leon and Norma Hess Centre for Science and Medicine

Mount Sinai Cardiovascular Institute | October 2011 to June 2014


Additional Information


Ongoing research support


02-0163 (Fuster) Fuster (PI) 1/1/14-12/31/14

Safra Foundation

Coronary Revascularization in Diabetic Patients, Follow-up

The major goal of this clinical trial is to define the optimal management strategy for diabetic patients with multivessel coronary artery disease.

Role: Co-PI


Grant Agreenment n° 241559 Fuster (PI) 1/1/12-1/1/15

Funded by the 7th Framework Programme

Fixed-dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS) project

The major goal is to study reasons for non-adherence to medication as well as studying the impact of a fixed doe combination polypill on adherence in a post-MI population.

Role: Scientific Coordinator


Astra Zeneca Fuster V (PI), Castellano JM Co-PI Aim 1. 6/1/2014-1/1/2018

The unifying purpose of TANSNIP (composed of four different aims) is to enable a model based on detection, quantification and characterization of subclinical atherosclerosis to enhance risk stratification and enable novel targeted therapies and risk reduction strategies. This award will consolidate a transatlantic network of world leading innovators in the fields of cardiovascular (CV) imaging, diagnostics and clinical trials.

AIM-1 will be carried out in a relatively low-risk population (ongoing PESA-CNIC cohort), and its objective is to study whether a personalized worksite based lifestyle intervention, driven by imaging data (3D-ultrasound of carotid and ilio-femoral arteries, and coronary calcification) results in changes in behavior, improved control of risk factors and reduced progression of subclinical atherosclerosis plaque burden (SAPB). Output: Non-pharmacological worksite lifestyle intervention validated against modification of conventional risk factors.

Role: Co-PI

SECURE (Secondary Prevention of Cardiovascular Disease in the Elderly)

H2020 PHC 17 Fuster V PI/Castellano JM(Co-PI) 18/1/2015-18/1/2020

The SECURE trial will test Trinomia® (a fixed dose combination polypill) for secondary CV prevention in the elderly population (≥ 65 years old) in the setting of an acute myocardial infarction (AMI – both ST elevation and non-ST elevation myocardial infarction (MI)). The principal objective of SECURE is to evaluate the potential benefit of Trinomia® as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of CV events (death from CV causes, nonfatal MI, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately).

Role: Co-PI


Selected Publications

  • [(18)F]-FDG PET and localized fibrous mesothelioma. Cortes J, Rodriguez J, Garcia-Velloso MJ, Rodriguez-Espiteri N, Boan JF, Castellano JM, Torre W. Lung. 2003;181(1):49-54.
  • Association of plasma cardiotrophin-1 with inappropriate left ventricular mass and cardiac dysfunction in essential hypertension. López B, Castellano JM, González A, Barba J, Díez J. Hypertension, 2007; 50 (5) 977-983.
  • Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. Alegria E, Castellano JM, Alegria A. Revista Española de Cardiología. 2008; 61:752-64.
  • Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Mastrobuoni S, Bastarrika G, Ubilla M, Castaño S, Azcarate P, Barrero EA, Castellano JM, Herreros J, Rabago G. Transplantion. 2009; 87: 587-590.
  • Anticoagulation during pregnancy in patients with a prosthetic heart valve. Castellano JM, Narayan RL, Vaishnava P, Fuster V. Nature Reviews Cardiology. 2012 May 15; 9(7): 415-24.
  • Are we ignoring the dilated thoracic aorta? Castellano JM, Kovacic JC, Sanz J, Fuster V. Annals of the New York Academy of Science. 2012 Apr; 1254: 164-74.
  • Atrial fibrillation, stroke, and quality of life. Chinitz JS, Castellano JM, Kovacic JC, Fuster V. Annals of the New York Academy of Science. 2012 Apr;1254:140-50.
  • The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Kovacic JC, Castellano JM, Fuster V. Annals of the New York Academy of Science 2012 Apr;1254:99-105
  • Cardiovascular defense challenges at the basic, clinical, and population levels. Kovacic JC, Castellano JM, Fuster V. Annals of the New York Academy of Science 2012 Apr;1254:1-6.
  • Quantitative assessment of right ventricular function in pectus excavatum. Narayan RL, Vaishnava P, Castellano JM, Fuster V. Journal of Thoracic and Cardiovascular Surgery. 2012 May;143(5):e41-2. Epub 2012 Feb 27.
  • The Influence of Obesity on the Assessment of Carotid Intima-Media Thickness. Gallego J, Irimia P, Martinez-Vila E, Barba J, Guembe MJ, Varo N, Castellano JM, Vines J, Dıez J. Journal of Clinical Ultrasound 2012; 40 (8):479–485.
  • A very unusual cause of mechanical left ventricular outflow tract obstruction. Castillo J, Castellano JM, Fuster V, Adams D. European Journal of Cardio-Thoracic Surgery 2013; 44: 579–580.
  • Coronary Vasospasm Due to Fibromuscular Dysplasia: the Long Bridge to Transplant. Castellano JM, Vaishnava P, Castillo J, Anyanwu A, Fuster V. Circulation Heart Faiulre, 2013;6:e31-e32.
  • Medical non-adherence: aiming at strategies for a complex problem. Castellano JM, Copeland-Halperin R, Fuster V. Global Heart 2013; 8 (3): 263-271.
  • Marfan’s Syndrome: Clinical, Surgical and Anesthetic Considerations. Castellano JM, Silvay G, Castillo J. Seminars in Cardiothoracic and Vascular Anesthesia (Epub ahead of print, DOI: 10.1177/1089253213513842).
  • Mechanisms of Stroke in Atrial Fibrillation. Castellano JM, Chinitz J, Willner J, Fuster V. Cardiac Electrophysiology Clinics 2014; 6: 5–15.
  • Evolution of the polypill concept and ongoing clinical trials. Castellano JM, Sanz G, Fuster V. Canadian Journal of Cardiology, 2014; 30 (5) 520-526.
  • The relationships between cardiovascular disease and diabetes. Kovacic J, Castellano JM, Farkouh M, Fuster V. Endocrinology Clinics of North America (2014); 43(1):41-57.
  • Promotion of Global Cardiovascular Health: strategies, challenges, and opportunities. Castellano JM, Narula J, Castillo J, Fuster V. Revista Española de Cardiología. doi: 10.1016/j.recesp.2014.01.024. [Epub ahead of print]
  • Promotion of cardiovascular health in three stages of life: never too early, never too late. Castellano JM, Peñalvo J, Bansilal S, Fuster V. Revista Española de Cardiología. doi: 10.1016/j.recesp.2014.03.012. [Epub ahead of print])
  • A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. Castellano JM, Sanz G, Garrido E, Bansilal S, Fuster V. Journal of the American College of Cardiology, 2014; 64:613-621.
  • Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Pozo E, Kanwar A, Deochand R, Castellano JM, Naib T, Pazos-López P, Osman K, Cham M, Narula J, Fuster V, Sanz J. Heart. 2014 Jul 10. doi: 10.1136/heartjnl-2014-305710. [Epub ahead of print]
  • Polypill: Chimera or Reality? Sanz G, Castellano JM, Fuster V. Revista Española de Cardiología. 2014 Jul 22. doi: 10.1016/j.recesp.2014.05.002. [Epub ahead of print]
  • A Polypill Strategy to Improve Adherence: Results From the FOCUS Project.

Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, Guzmán L, Linares JC, García F, D’Aniello F, Arnáiz JA, Varea S, Martínez F, Lorenzatti A, Imaz I, Sánchez-Gómez LM, Roncaglioni MC, Baviera M, Smith SC Jr, Taubert K, Pocock S, Brotons C, Farkouh ME, Fuster V. Journal of the American College of Cardiology. 2014 Sep 1. pii: S0735-1097(14)05941-5. doi: 10.1016/j.jacc.2014.08.021. [Epub ahead of print]

  • Polypill, el policomprimido cardiovascular: del concepto a la realidad en España. Castellano JM, Fuster V. Rev Esp Cardiol. 2015, 15(E):19-24.
  • Global burden of CVD: focus on secondary prevention of cardiovascular disease. Bansilal S, Castellano JM, Fuster V. Int J Cardiol. 2015, 201(Suppl 1):S1-S7.
  • The cardiovascular polypill: clinical data and ongoing studies. Castellano JM, Bueno H, Fuster V. Int J Cardiol. 2015, 201(Supplement 1):S8-S14.
  • The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. Tamargo J, Castellano JM, Fuster V. Int J Cardiol. 2015, 201 (Suppl 1):S15-S22.
  • Risk factors and therapeutic coverage at 6 years in patients with previous myocardial infarction: the CASTUO study. Félix-Redondo FJ, Lozano Mera L, Consuegra-Sánchez L, Garcipérez de Vargas FJ, Castellano JM, Fernández-Bergés D. Open Heart 2016;3:e000368. doi:10.1136/openhrt-2015-000368
  • Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Barrios V, Kaskens L, Castellano JM, Cosin-Sales J, Ruiz JE, Zsolt I, Fuster V, Gracia A. Rev Esp Cardiol (Engl Ed). 2016 Jul 26. pii: S1885-5857(16)30151-7. doi: 10.1016/j.rec.2016.05.009. [Epub ahead of print].
  • Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C, Garcia-Alonso F, Lizano I, Arnold RJ1, Rajda J, Steinberg G, Fuster V. J Am Coll Cardiol. 2016 Aug 23;68(8):789-801. doi: 10.1016/j.jacc.2016.06.005.


Book Chapters

  • Psychological aspects of cardiovascular heart disease. Castellano JM, Nasarre E, Alegria E. Sociedad Española de Cardiología. 2006
  • Practical questions in Clinical Cardiology. Castellano JM, Moreno J, Alegria E. Sociedad Española de Cardiología. 2006
  • Lipidologia: Presente y Futuro. Del metabolismo y la biología vascular, a la práctica clínica. EDITORES: Jorge Vilariño, Alberto Lorenzatti. 2013. Non-invasive evaluation of the dyslipemic patient. JM Castellano and V Fuster.
  • Atherothrombosis. Castellano JM, Kovacic J, Fuster V. Panvascular Medicine, second edition. Editors: Peter Lanzer, Eric Topol. 2014. DOI 10.1007/978-3-642-37078-6.
  • Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. Yu J, Mehran R, Castellano JM, Fuster V. Panvascular Medicine, second edition. Editors: Peter Lanzer, Eric Topol. 2014. DOI 10.1007/978-3-642-37078-6.
  • Coronary Heart Disease Risk Factors. Mount Sinai Expert Guidelines on Cardiovascular Disease. Castellano JM, Castillo J, Narula J. (in press).
  • Urgencias Médicas. Claves diagnósticas y terapéuticas. ISBN: 978-84-608-6524-7. 2016. Patología vascular aguda. M Blanch, LM Izquierdo, JM Castellano, JF Varona


Selected Invited Conferences

  • Congreso de la Sociedad Española de Cardiología, Octubre 2009, Barcelona, Spain.

LA OBESIDAD Y EL SOBREPESO: LA EPIDEMIA QUE ALCANZA AL CARDIÓLOGO. La grasa epicardica: ¿culpable, transeúnte o marcador de riesgo cardiovascular?

  • AHA 2012. November 4th 2012, Los Angeles.

Cardiac Amyloid: Ethiological, Diagnostic and Therapeutic Advances.

  • NY MOUNT SINAI CNIC PROGRAM. May 17th 2013, New York City.

Gene Therapy in Advanced Heart Failure: Lessons from CUPID.

  • Mitral Conclave. June 6th 2014, Madrid, Spain.

Enfermedad Degenerativa: Epidemiologia y Espectro de la Enfermedad.

  • III Jornada de Actualización Cardiovascular CIEC. September 19th 2014, Madrid, Spain

Prevención Cardiológica y Vascular: Retos Presentes y Perspectivas Futuras.

  • XVI Congreso Nacional de Cardiología ANCAM. October 2014, Cancun, Mexico.

New Evidences on the Use of a Polypill Strategy for Secondary Cardiovascular Prevention

  • Congreso Sociedad Española de Cardiología. 31 October 2014, Santiago de Compostela, Spain.

The Impact of Therapeutic Adherence on Cardiovascular Prevention

  • Congreso Sociedad Andaluza de Hipertensión Arterial. 8 November 2014, Jerez de la Frontera, Spain.

Strategies to Improve Adherence: Role of the Polypill in Cardiovascular Prevention.

  • 11th Global Cardiovascular Clinical Trialists Forum. December 5-7 2014 Washington DC, USA.

The problem of CV Drug Adherence Worldwide.

  • 47th Annual Cardiovascular Symposium. December 12-14, 2014. New York, USA.

The polypill for secondary prevention is entering the cardiovascular field: worldwide interest based on better adherence and economics.

  • 16 Congreso de Investigación en Salud Publica: Marzo 2015, Cuernavaca, México.

Revisión de ensayos recientes y en curso sobre la polipildora como se está construyendo la evidencia.

  • XVIII Congreso de la Sociedad Canaria de Cardiología. Marzo 2015, Las Palmas de Gran Canaria, Spain.

La polipildora en prevención cardiovascular: del concepto a la realidad.

  • XI Reunión de Riesgo Vascular Sociedad Española de Medicina Interna. Abril 2015, Madrid, Spain.

Polipildora: una realidad en el presente, una esperanza en el futuro.

  • Congreso Sociedad Latino Americana Medicina Interna (SOLAMI). May 2015. Punta Cana, Republica Dominicana.

Plenary Session. Interventions in public health.

  • XXV European Society of Hypertension. June 12-15 2015. Milan, Italy.

The Polypill: a reality in cardiovascular disease prevention and treatment.

  • Sociedad Chilena de Cardiologia. Departamento de Cardiologia Preventiva. June 23rd. Santiago de Chile.

Global burden of cardiovascular disease: challenges and opportunities in secondary prevention.

  • International Society of Cardiovascular Pharmacotherapy. June 26 2015. Buenos Aires, Argentina.

The burden of therapeutic adherence: challenges and opportunities.

  • European Society of Cardiology Congress. August 31st 2015, London, UK.

Importance of Adherence in Improving Outcomes in Secondary Cardiovascular Prevention.

  • Reunión Anual de la Sección de Cardiologia Geriátrica. Córdoba, Spain, September 18th, 2015.

Cumplimiento terapéutico y polifarmacia en el anciano: ¿hay un lugar para la “polypill”?

  • 22 Congreso de Sociedad Gallega de Hipertensión. Sanxenxo, Spain, October 2 – 3 2015.

Ventajas e Inconvenientes de la Polipíldora.

  • 59 Symposium de la Alianza Mundial para la Prevención Cardiovascular. Bilbao, October 21-23 2015.

La Polypill como estrategia de promoción de la salud cardiovascular.

  • Jornada sobre presente y futuro para los pacientes del Corazón. Madrid, November 10 2015

Investigación traslacional en Cardiología.

  • 4th National Observatory of Adherence Meeting. Madrid, November 11th 2015.

Cardiovascular Polypill as a strategy to improve adherence: a new reality in cardiovascular prevention.

  • Prevention of Cardiovascular Events. The challenge of Non-Adherence to Treatment: Innovation in Public Health Intervention. December 1st 2015

European Parliament, Brussels.

  • Congreso Sociedad Mexicana de Cardiología, Acapulco, 21 – 25 November 2015
  1. Novel strategies in secondary prevention.
  2. La polipíldora cardiovascular: una (r)evolución en el tratamiento crónico de la cardiopatía isquémica.
  • XXV Congreso Interamericano de Cardiología, Santiago de Chile. 4-7 diciembre 2015.
  1. Secondary prevention in ischemic heart disease. Much room for improvement.
  2. The cardiovascular polypill: from concept to reality.
  • IX Curso de Fisiopatología Cardiovascular: del Síntoma a los Genes. Madrid, 11 y 12 de Diciembre 2015.

¿Polipíldora: a quién y por qué?

  • EuroHeartCare: Athens, Greece, 15-16 April 2016.

Detecting and managing non-adherence in secondary prevention of cardiovascular disease.

  • Curso Prevención Cardiovascular Sociedad Chilena de Cardiologia. Santiago de Chile, 22-23 April 2016.

– Advances in bioimaging: role of subclinical atherosclerosis.

– Sedentarism and cognitive impairment: new areas of cardiovascular health promotion.

– Is the polypill an alternative for achieving improved secondary prevention?

  • 5th Symposium on Stroke, Cognitive Impairment and Neuropathy Management. Madrid, 27-28 April 2016.

Polypill, a revolution in secondary prevention.

  • XVIII International Symposium. Update in Cardiovascular Therapies. Madrid, May 6th 2016.

A different strategy, the cardiovascular polypill. You have to convince me.

  • 28th World Cardiology Congress, Mexico City, Mexico, June 4-7, 2016

Adherence to therapy: impact on morbidity and mortality

  • European Society of Hypertension, Paris, France June 10-13, 2016

Is the CV Polypill a Solution to Reduce the Gap?

  • 5th Asia-Pacific Symposium on Stroke and Cognitive Impairment. Hanoi, Vietnam, June 27th, 2016.

Polypill, a revolution in secondary prevention.

Teaching, Consulting and Advising

  • Fundación de Investigación HM, Executive Committee

Av Monte Montepríncipe s/n Urb Montepríncipe, Madrid.

Phone: (+34)917247000

June 2015 to present.

  • Insight into cardiovascular pathology research: a comprehensive molecular, physiological, clinical and practical approach (BMM9).

Autónoma University Masters Degree in Biosciences| February 2016

  • Associate Professor, CEU San Pablo Medical School.

Estudio Integral de la Enfermedad Cardiovascular 2013-2014

Estudio Integral de la Enfermedad Cardiovascular 2014-2015

Introducción a la investigación translacional en medicina cardiovascular 2015-2016

Medicina cardiovascular. Responsable de la asignatura. 2015-2016

Introducción a la investigación translacional en medicina cardiovascular 2016-2017

Medicina cardiovascular. Responsable de la asignatura. 2016-2017

  • European Commission H2020 Expert Reviewer, Non-communicable diseases and the challenge of healthy aging. H2020-SC1-2016,2017. Topic: PM-09


Prizes and Awards

  • Accésit al Premio Juan Letona: best translational research 2015.

FOCUS Project. Awarded to José M. Castellano.

Madrid, June 2015

  • Premio Diario Medico: best medical ideas of 2015.

Polypill project, awarded to CNIC.

Barcelona, November 2015

  • XI Premio madri+d al mejor proyecto europeo de I+D en Cooperacion por el poryecto SECURE


Scientific Meetings Board and Organizing Committees

Diabetes Course: The New York Experience, Mount Sinai Hospital and NYU Langone Medical Center

Strategies to improve cardiovascular prevention in the diabetes arena.

December 4-5 2014, New York, USA.

Program Co-Director.

Scientific Program at CNIC: the polypill project and beyond.

Madrid, July 22 2015.

Scientific Program Director.

Scientific Program at CNIC: the polypill project and beyond.

Madrid, July 27 2016.

Scientific Program Director.


Selected Abstract Presentations

  • Diagnostic Accuracy of Myocardial T1 Mapping in Cardiac Amyloidosis. Jose Maria Castellano, Eduardo Pozo, Anubhav Kanwar, Sarayu Ramachandran, Rajiv Deochand, Pablo Pazos, Ines Garcia‐Lunar, Matthew Cham, Valentin Fuster, Javier Sanz. ACC 2013, San Francisco.
  • Atrial delayed enhancement is associated with the severity of diastolic dysfunction in cardiac amyloidosis. Eduardo Pozo, Jose M Castellano, Tara Naib, Rajiv Deochand, Anubhav Kanwar, Ines Garcia-Lunar, Pablo Pazos, Jill Kalman, Valentin Fuster and Javier Sanz. Abstracts of the 16th Annual SCMR Scientific Sessions.
  • Revisiting morphological features of cardiac amyloid with cardiac magnetic resonance. Eduardo Pozo, Jose M Castellano, Rajiv Deochand, Anubhav Kanwar, Pablo Pazos, Ines Garcia-Lunar, Matthew D Cham, Adam Jacobi, Jagat Narula, Valentin Fuster and Javier Sanz. Abstracts of the 16th Annual SCMR Scientific Sessions.
  • Cardiac Amyloid Burden Estimated with Myocardial T1 Mapping is Associated with Severity of Cardiac Disease. Eduardo Pozo, Rajiv Deochand, Anubhav Kanwar, Sarayu Ramachandran, Jose M Castellano, Matthew Cham, Valentin Fuster, Jagat Narula, Javier Sanz. AHA Scientific Sessions, Los Angeles, Nov 07, 2012.
  • Value of Classical Criteria for Diagnosis of Cardiac Amyloid in the Cardiac Magnetic Resonance Era. Eduardo Pozo, Jose M Castellano, Rajiv Deochand, Anubhav Kanwar, Maria Eduarda Menezes de Siqueira, Jorge Rodriguez-Garrido, Teresa Arias, Matthew Cham, Jagat Narula, Valentin Fuster, Javier Sanz. ACC Scientific Sessions, Washington, March 29, 2014,
  • Assessing the Impact of Medication Adherence on Long-term Outcomes Post Myocardial Infarction. S. Bansilal, JM Castellano, HG. Wei, EG. Vinado, A. Freeman, CM. Spettell, FG. Alonso, G. Steinberg, G. Sanz, V. Fuster. ESC Congress, Barcelona 2014 (Late Braking Trial Presentation, registries).
  • Assessing the impact of medication adherence on long-term outcomes in patients with diabetes. S Bansilal, HG Wei HG, JM Castellano, EV Garrido, AN Freeman, G Sanz, FG Alonso, Spettell, G Steinberg, V Fuster. ACC Congress, San Diego 2015.
  • Cost of Non-Adherence to Medication in a Post-MI Population. Ester Garrido, R.J. Arnold, Sameer Bansilal, JM Castellano, H.G. Wei, A. Freeman, F. Garcia-Alonso, C. Espinosa, I Lizano C, Spettell, G Steinber, V. Fuster Value in Health 05/2015; 18(3):A3. DOI: 10.1016/j.jval.2015.03.018


Previous Professional Experience

  • Junior Researcher, Centro Nacional de Investigaciones Cardiovasculares, (CNIC). January 2014-August 2014.
  • Assistant Professor, Universidad CEU San Pablo, Madrid, Spain, September 2013 to present.
  • Completed Residency in the Department of Cardiology, Clínica Universidad de Navarra, Pamplona, Spain, May 2005-2010.
  • Coronary Care Unit rotation St. George´s Hospital, London. September-December 2008.
  • Assistant professor, School of Nursing, postgraduate program in cardiology, Clínica Universidad de Navarra, Pamplona, Spain, 2006-2010.
  • Massachusetts General Hospital, Harvard Medical School, Undergraduate stay as part of BSc program. June-September 1997.
  • Deaconess Hospital, Harvard Medical School. Undergraduate stay as part of BSc program. June-September 1996


Professional Memberships

  • Speaker, Preventive Cardiology and Rehabilitation Section of the Spanish Society of Cardiology 2007-2010.
  • International Editorial Committee, Revista Española de Cardiología, January 2013 to present.
  • Editor, Journal of the American College of Cardiology (JACC), January 2014 to present.
  • International Editorial Reviewer Board, Journal of Cardiovascular Surgery. May 2014 to present.
  • Editorial Board, Cochrane Heart. June 2016 to present.
  • Reviewer Board: American Journal of Cardiology; American Journal of Medicine; Global Heart; Catheterization & Cardiovascular Interventions; Revista Española de Cardiologia, International Journal of Clinical Medicine.
  • Spanish society of Cardiology.
  • European Society of Cardiology.
  • European Association for Cardiovascular Prevention and Rehabilitation (EACPR)